XBiotech Inc

XBITNASDAQUSD
2.59 USD
0.00 (0.04%)🟢PRE MARKET (AS OF 04:10 AM EDT)
🟢Market: OPEN
Open?$2.58
High?$2.58
Low?$2.58
Prev. Close?$2.58
Volume?N/A
Avg. Volume?41.2K
Bid / Ask
Bid?$2.20 × 100
Ask?$2.96 × 100
Spread?$0.76
Midpoint?$2.58
Valuation & Ratios
Market Cap?78.7M
Shares Out?30.5M
Float?16.6M
Float %?54.4%
P/E Ratio?N/A
P/B Ratio?0.56
EPS?-$1.49
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?16.01Strong
Quick Ratio?16.01Strong
Cash Ratio?15.83Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score
100/100
P/E?
N/A
P/B?
0.56CHEAP
P/S?
N/A
P/FCF?
N/A
EV/EBITDA?
0.9CHEAP
EV/Sales?
N/A
Returns & Efficiency
ROE?
-32.5%WEAK
ROA?
-30.3%WEAK
Cash Flow & Enterprise
FCF?$-40209000
Enterprise Value?$-46892654
Fundamentals ratios updated end of day
xxx
Related Companies
Loading...
News
Profile
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
Employees
85
Market Cap
76.5M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2015-04-15
Address
5217 WINNEBAGO LANE
AUSTIN, TX 78744
Phone: 512-386-2900